Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?

30 April 2017 (13:35 - 13:50)

Organised by:

About the speaker

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail

Introduction & remarks.

Professor N. Danchin (Paris, FR)

Presentation thumbnail

Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

Professor M. Cowie (London, GB)

Presentation thumbnail

Options in thrombosis prevention and vascular health – What’s on the horizon?

Professor K. Fox (Edinburgh, GB)

Presentation thumbnail

Broadening the evidence base for rivaroxaban in heart failure.

Professor B. Greenberg (La Jolla, US)

Presentation thumbnail

Q&A and closing remarks.

Professor M. Cowie (London, GB)

Access the full session

Session thumbnail

Management of co-morbidities in heart failure - Exploring new frontiers

The Event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

30 April 2017 13:35 CET

You may be interested in

Congress Presentation

The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?

30 June 2021

Congress Session

What’s on the horizon in heart failure: precision medicine and tailored treatment

18 May 2025

Congress Session

Frailty and dementia in heart failure

31 August 2026

Congress Presentation

Heart failure and comorbidities

29 June 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources